ZG006 for injection, in combination with etoposide and cisplatin, received approval for clinical trials
November 14, 2025
Source: drugdu
72
Southern Finance reported on November 13th that the company recently received a "Drug Clinical Trial Approval Notice" from the National Medical Products Administration, approving a clinical trial of ZG006 for injection in combination with etoposide and cisplatin for advanced neuroendocrine carcinoma. This clinical trial approval will not have a significant impact on the company's recent performance. However, given the long development cycle, numerous approval processes, and substantial R&D investment required for pharmaceuticals, they are susceptible to uncertainties. Investors are advised to exercise caution and be aware of investment risks.
https://finance.eastmoney.com/a/202511133563656229.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Breaking the Mold and Forging a New Path! From Insulin Technology Pioneer to Global Innovation Competitor December 4, 2025
- A subsidiary of Kingfriend Pharmaceutical Co., Ltd. has received FDA approval for its self-developed injectable dapavancin December 4, 2025
- Major ophthalmic new drug successfully completed Phase III trials December 4, 2025
- Simcere Pharmaceutical and Wangshan Wangshui have reached an exclusive licensing agreement for deuterium remidevir hydrobromide for new indications such as RSV infection December 4, 2025
- SAL0140 tablets approved for clinical trials for the treatment of chronic kidney disease December 4, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
